Short and long-term economic implications of biosimilars

ABSTRACT

Introduction

Biosimilars are gaining popularity due to their ability to offer comparable therapeutic benefits at potentially lower costs.

Areas covered

This article analyses studies that compare the cost savings of biosimilars with biologics. It also explores market competition dynamics and the impact of policies in countries. The focus is on the advantages of biosimilars in oncology and rheumatological treatments while considering broader economic implications for the pharmaceutical industry such as market displacement, pricing strategies and their influence on innovation and healthcare sustainability.

Expert opinion

The introduction of biosimilars marks a shift in healthcare economics by offering cost reductions and long-term potential for economic balance. However, I also recognize challenges related to research methodologies and regulatory inconsistencies across countries. To fully capitalize on their potential, future research and development in the field of biosimilars must emphasize harmonized approaches and comprehensive studies that ensure both cost containment in healthcare and wider access, to high quality treatments.

KEYWORDS:

• Biosimilars
• biological therapy
• economic implications
• cost-savings
• medication cost-effectiveness

Article highlights

• Biosimilars has a role in enhancing access to treatments for conditions like cancer and rheumatological diseases.

• Significant cost savings in oncology, with biosimilars potentially saving millions of euros annually.

• Regulatory costs and the need for educational materials for healthcare providers are additional factors.

• Biosimilars could democratize healthcare by making treatments more accessible and affordable.

• Longitudinal studies and robust economic models are needed for better understanding.

Declaration of interest

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

The paper was not funded.